Ra Medical Systems Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ra Medical Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMED, but not buy additional shares or sell existing shares.
View analyst ratings for Ra Medical Systems or view top-rated stocks.

Wall Street analysts have given Ra Medical Systems a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ra Medical Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ra Medical Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Ra Medical Systems.

Ra Medical Systems, Inc. (NYSE:RMED) released its quarterly earnings data on Tuesday, May, 11th. The company reported ($2.48) EPS for the quarter, beating analysts' consensus estimates of ($2.94) by $0.46. The business earned $1.12 million during the quarter. Ra Medical Systems had a negative net margin of 857.56% and a negative trailing twelve-month return on equity of 151.70%.
View Ra Medical Systems' earnings history.

Ra Medical Systems' stock was trading at $31.4075 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RMED stock has decreased by 83.4% and is now trading at $5.22.
View which stocks have been most impacted by COVID-19.

Ra Medical Systems shares reverse split on Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 16th 2020. An investor that had 100 shares of Ra Medical Systems stock prior to the reverse split would have 4 shares after the split.

2 analysts have issued 1-year target prices for Ra Medical Systems' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Ra Medical Systems' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 34.1% from the stock's current price.
View analysts' price targets for Ra Medical Systems or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ra Medical Systems include Delcath Systems (DCTH), Neovasc (NVCN), Aethlon Medical (AEMD), Obalon Therapeutics (OBLN), Plus Therapeutics (PSTV), AIT Therapeutics (AITB), Hancock Jaffe Laboratories (HJLI), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Daxor (DXR), INVO Bioscience (INVO), InspireMD (NSPR), Sintx Technologies (SINT), Vivos (RDGL) and InVivo Therapeutics (NVIV).
View all of RMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Medical Systems investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Novan (NOVN), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL) and Zosano Pharma (ZSAN).

(RMED) raised $50 million in an initial public offering on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

Ra Medical Systems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Royce & Associates LP (9.75%), Renaissance Technologies LLC (4.78%), Dowling & Yahnke LLC (2.10%), GSA Capital Partners LLP (1.52%), Virtu Financial LLC (0.90%) and Bank of New York Mellon Corp (0.59%). Company insiders that own Ra Medical Systems stock include Dean Irwin, Jonathan Will Mcguire, Martin Burstein, Martin J Colombatto, Richard Mejia Jr and William R Enquist.
View institutional ownership trends for Ra Medical Systems.

RMED stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Dowling & Yahnke LLC, GSA Capital Partners LLP, Virtu Financial LLC, Bank of New York Mellon Corp, Morgan Stanley, Geode Capital Management LLC, and Renaissance Technologies LLC. Company insiders that have bought Ra Medical Systems stock in the last two years include Jonathan Will Mcguire, Martin J Colombatto, Richard Mejia Jr, and William R Enquist.
View insider buying and selling activity for Ra Medical Systems or or view top insider-buying stocks.

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMED stock can currently be purchased for approximately $5.22.

Ra Medical Systems has a market capitalization of $17.00 million and generates $4.41 million in revenue each year.

Ra Medical Systems employs 86 workers across the globe.

The official website for Ra Medical Systems is www.ramed.com.

Ra Medical Systems is headquartered at 2070 Las Palmas Drive, Carlsbad CA, 92011.

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]